Rituxan. Rituxan (rituximab) Description
|
|
- Alyson Shaw
- 6 years ago
- Views:
Transcription
1 Federal Employee Program 1310 G Street, N.W. Washington, D.C Fax Subject: Rituxan Page: 1 of 9 Last Review Date: December 3, 2015 Rituxan Description Rituxan (rituximab) Background Rituxan is a monoclonal antibody that is manufactured through biotechnology methods rather than by the human body s own immune system. The drug works by greatly reducing the number of specific immune cells in the blood, known as B-cells. The drug binds to a particular protein, the CD20 antigen, on the surface of normal and malignant B-cells, making it easier for the patient s immune system to attack the cancer cell as if it were a foreign pathogen. With the targeted mechanism of action of Rituxan to B-cells, it is used in the treatment of chronic lymphocytic leukemia (CLL), a slowly progressing blood and bone marrow cancer, that arises from a group of white blood cells known as B-cells, in the treatment of CD20 positive, Non- Hodgkin s Lymphoma (NHL), which is a type of cancer that occurs in B-cells, and in the treatment of rheumatoid arthritis (RA) which B-cells are believed to play an important role in RA (1,2,4). Rituxan, in combination with glucocorticoids (steroids), is used to treat patients with Wegener s granulomatosis (WG) and microscopic polyangiitis (MPA), two rare disorders that cause blood vessel inflammation (vasculitis). Vasculitis in patients with WG and MPA can lead to tissue damage. WG mostly affects the respiratory tract (sinuses, nose, trachea, and lungs) and kidneys, while MPA commonly affects the kidneys, lungs, nerves, skin, and joints (3). Regulatory Status FDA approved indications include: (2)
2 Subject: Rituxan Page: 2 of 9 Non-Hodgkin s Lymphoma (NHL) Rituxan is indicated for the treatment of patients with: Relapsed or refractory, low-grade or follicular, CD20-positive, B-cell NHL as a single agent Previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to Rituxan in combination with chemotherapy, as single-agent maintenance therapy Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL, as a single agent, after first-line CVP chemotherapy Previously untreated diffuse large B-cell, CD20-positive NHL in combination with CHOP or other anthracycline-based chemotherapy regimens Chronic lymphocytic leukemia (CLL) Rituxan is indicated, in combination with fludarabine and cyclophosphamide (FC), for the treatment of patients with previously untreated and previously treated CD20-positive CLL. Rheumatoid arthritis (RA) Rituxan in combination with methotrexate is indicated for the treatment of adult patients with moderately- to severely-active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies. Granulomatosis with Polyangiitis (GPA) (Wegener s Granulomatosis) and Microscopic Polyangiitis (MPA) Rituxan in combination with glucocorticoids, is indicated for the treatment of adult patients with Granulomatosis with Polyangiitis (GPA) (Wegener s Granulomatosis) and Microscopic Polyangiitis (MPA). Limitations of use: Rituxan is not recommended for use in patients with severe, active infections (2). Rituxan has several boxed warnings regarding fatal infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, and progressive multifocal leukoencephalopathy (PML) resulting in death (2). Rituxan can cause severe, including fatal, infusion reactions.. Carefully monitor patients during infusions. Discontinue Rituxan infusion in patients who develop severe (grade 3 or 4) infusion reactions and administer medical treatment (2). Acute renal failure, hyperkalemia, hypocalcemia, hyperuricemia, or hyperphosphatemia from tumor lysis, some fatal, can occur within hours after the first infusion of Rituxan in patients
3 Subject: Rituxan Page: 3 of 9 with non-hodgkin lymphoma (NHL). Patients at high risk for tumor lysis syndrome should be administered aggressive intravenous hydration, anti-hyperuricemic agents, and their renal function should be monitored (2). Mucocutaneous reactions, some with fatal outcome, can occur in patients treated with Rituxan. Rituxan should be discontinued in patients who experience a severe mucocutaneous reaction (2). Serious, including fatal, bacterial, fungal, and new or reactivated viral infections can occur during and following the completion of Rituxan-based therapy. Discontinue Rituxan for serious infections and institute appropriate anti-infective therapy (2). Rituxan infusions should be discontinued in patients that develop serious or life-threatening cardiac arrhythmias. Perform cardiac monitoring during and after all infusions of Rituxan for patients who develop clinically significant arrhythmias, or who have a history of arrhythmia or angina (2). The safety of immunization with live viral vaccines following Rituxan therapy has not been studied and vaccination with live virus vaccines is not recommended (2). In patients with lymphoid malignancies, during treatment with Rituxan monotherapy, obtain complete blood counts (CBC) and platelet counts prior to each Rituxan course. During treatment with Rituxan and chemotherapy, obtain CBC and platelet counts at weekly to monthly intervals and more frequently in patients who develop cytopenias. In patients with rheumatoid arthritis, granulomatosis with polyangiitis (GPA), or microscopic polyangiitis (MPA), obtain CBC and platelet counts at two to four month intervals during Rituxan therapy. The duration of cytopenias caused by Rituxan can extend months beyond the treatment period (2). Off Label Uses: There are a number of important off-label uses for the use of Rituxan (rituximab) that are supported by the medical literature. The inclusion of the following conditions is based on the studies cited. Other Non-Hodgkin s Lymphomas (5) 1. Burkitt lymphoma 2. Gastric MALT lymphoma 3. Non-gastric MALT lymphoma
4 Subject: Rituxan Page: 4 of 9 4. Nodal Marginal Zone lymphoma 5. Mantle cell lymphoma 6. AIDS-Related B-cell lymphomas 7. Post-transplant lymphoproliferative disorder 8. Primary cutaneous B-cell lymphoma 9. Splenic marginal zone lymphoma 10. Hairy Cell Leukemia Other Conditions 1. Waldenstrom s macroglobulinemia 6 2. Steroid refractory chronic graft vs. host disease 7 3. Immune thrombocytopenic purpura 8 4. Thrombotic thrombocytopenic purpura Refractory autoimmune hemolytic anemia 9 Rituxan as monotherapy or in conjunction with various chemotherapy agents as well as other monoclonal antibodies is supported by clinical trial data and NCCN guideline recommendations (5). The following chemoimmunotherapy regimens are used for either first-line therapy or relapsed/refractory therapy depending on the results of genetic testing and comorbidities in affected patients: (5) 1. Alemtuzumab + Rituxan 2. Bendamustine, Rituxan (BR) 3. CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) + Rituxan 4. HyperCVAD (cyclophosphamide,vincristine,doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine) + Rituxan 5. Dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) + Rituxan 6. HDMP (high-dose methylpredisolone) + Rituxan 7. Pentostatin, cyclophosphamide, Rituxan) (PCR) 8. CFAR (cyclophosphamide, fludarabine, alemtuzumab, Rituxan) 9. OFAR (oxaliplatin, fludarabine, cytarabine, Rituxan) 10. Lenalidomide + Rituxan Related policies Kyprolis, Imbruvica, Pomalyst, Revlimid, Velcade
5 Subject: Rituxan Page: 5 of 9 Policy This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims. Rituxan may be considered medically necessary in patients 18 years of age or older for the treatment of Non-Hodgkin s Lymphoma, B-Cell, CD20-Positive, which include Chronic Lymphocytic Leukemia, follicular lymphoma, diffuse large B-cell lymphoma, Burkitt lymphoma, gastric MALT lymphoma, non-gastric MALT lymphoma, nodal marginal zone lymphoma, mantle cell lymphoma, AIDS-Related B-cell lymphomas, post-transplant lymphoproliferative disorder, primary cutaneous B-cell lymphoma, splenic marginal zone lymphoma, moderate-to-severelyactive and hairy cell leukemia; Rheumatoid Arthritis (previously inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies), granulomatosis with polyangiitis (formerly Wegener's granulomatosis) (concurrent with glucocorticoid) or Microscopic Polyangiitis (concurrent with glucocorticoid). Rituxan may also be considered medically necessary in Waldenstrom s macroglobulinemia, steroid refractory chronic graft vs. host disease, immune thrombocytopenic purpura, thrombotic thrombocytopenic purpura, and refractory autoimmune hemolytic anemia. Rituxan may be considered investigational in patients who do not meet the criteria for medical necessity. Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Non-Hodgkin Lymphomas (NHL), B-Cell, CD20-Positive a. Chronic Lymphocytic Leukemia (CLL) b. Follicular lymphoma c. Diffuse large B-cell lymphoma d. Burkitt lymphoma e. Gastric MALT lymphoma f. Non-gastric MALT lymphoma g. Nodal Marginal Zone lymphoma h. Mantle cell lymphoma
6 Subject: Rituxan Page: 6 of 9 i. AIDS-Related B-cell lymphomas j. Post-transplant lymphoproliferative disorder k. Primary cutaneous B-cell lymphoma l. Splenic marginal zone lymphoma m. Hairy Cell Leukemia 2. Rheumatoid arthritis (RA) AND ALL of the following: a. 18 years of age or older b. Moderately- to severely-active RA c. Inadequate treatment response, intolerance, or contraindication to one or more tumor necrosis factor (TNF) antagonist therapies 3. Microscopic polyangiitis (MPA) AND ALL of the following: a. 18 years of age or older b. Currently taking a glucocorticoid 4. Granulomatosis with polyangiitis (formerly Wegener's granulomatosis) AND ALL of the following: a. 18 years of age or older b. Currently taking a glucocorticoid 5. Waldenström s macroglobulinemia 6. Steroid refractory chronic graft vs. host disease 7. Immune thrombocytopenic purpura 8. Thrombotic thrombocytopenic purpura 9. Refractory autoimmune hemolytic anemia AND ALL of the following:
7 Subject: Rituxan Page: 7 of 9 a. NOT using a Tumor Necrosis Factor (TNF) antagonist b. NOT using any of the following: Abatacept (Orencia) Tocilizumab (Actemra) Anakinra (Kineret) Tofacitinib (Xeljanz) c. NO use of a live vaccines, (Non-live vaccines should be administered at 4 weeks prior to a course of Rituxan). d. NO severe, active infections Tumor Necrosis Factor (TNF) antagonists include adalimumab (Humira), etanercept (Enbrel), cerolizumab pegol (Cimzia), golimumab (Simponi), and infliximab (Remicade). Prior Approval Renewal Requirements Same as above Policy Guidelines Pre - PA Allowance None Prior - Approval Limits Duration 12 months Prior Approval Renewal Limits Duration Rationale 12 months Summary Rituxan is a monoclonal antibody that is manufactured through biotechnology methods rather than by the human body s own immune system. The drug works by greatly reducing the number of specific immune cells in the blood, known as B-cells. The drug binds to a particular protein, the CD20 antigen, on the surface of normal and malignant B-cells, making it easier for the patient s immune system to attack the cancer cell as if it were a foreign pathogen. Rituxan is therefore used to treat diseases which are characterized by excessive numbers of B cells,
8 Subject: Rituxan Page: 8 of 9 overactive B cells, or dysfunctional B cells. This includes non-hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), microscopic polyangiitis (MPA), and granulomatosis with polyangiitis (1-4). Prior authorization is required to ensure the safe, clinically appropriate and cost effective use of Rituxan (rituximab) while maintaining optimal therapeutic outcomes. References 1. FDA Resource Pages. Food Drug Administration Website. FDA Approves Rituxan to Treat Chronic Lymphocytic Leukemia Rituxan [package insert]. South San Francisco, CA: Genentech Inc; August FDA Resource Pages. Food Drug Administration Website. FDA approves Rituxan to treat two rare disorders Rituxan Website. About NHL NCCN Clinical Practice Guidelines in Oncology: Non-Hodgkin s Lymphomas, version I. 2015; August NCCN Guidelines (NCCN Guidelines Waldenström s Macroglobulinemia / Lymphoplasmacytic Lymphoma, page WMPLP-2) 7. Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Fili C, Scime R, Milone G, Falda M, Vener C, Laszlo D, Alessandrino PE, Narni F, Sica S, Olivieri A, Sperotto A, Bosi A, Bonifazi F, Fanin R; GITMO (Gruppo Italiano Trapianto Midollo Osseo). Treatment of refractory chronic GVHD with rituximab: a GITMO study. 8. Bone Marrow Transplant Aug; 40(3):273-7). Medeot M, Zaja F, Vianelli N,Battista M, Baccarani M, Patriarca F, Soldano F, Isola M, De Luca S, Fanin R. Rituximab therapy in adult patients with relapsed or refractory ITP: long term follow-up results. Eur J Haematol May Bader-Meunier B, Aladjidi N, Bellmann F, Monpoux F, Nelken B, Robert A, Armari-Alla C, Picard C, Ledeist F, Munzer M, Yacouben K, Bertrand Y, Pariente A, Chaussé A, Perel Y, Leverger G. Rituximab therapy for childhood Evans syndrome. Haematologica Dec;92(12):1691-4) 10. Rituximab for refractory and or relapsing thrombotic thrombocytopenic purpura. Elliott, et al; Eur j Haematol Oct; 83(4):
9 Subject: Rituxan Page: 9 of 9 Policy History Date February 2012 September 2012 December 2012 March 2013 September 2013 March 2014 September 2014 December 2014 March 2015 June 2015 December 2015 Keywords Action Added Methotrexate (MTX) is required unless there is intolerance to MTX, contraindication to MTX or failure on MTX. Annual editorial and reference update Deleted requirement of concurrent fludarabine and cyclophosphamide therapy for CLL (NCCN guidelines include many other concurrent therapies) Added indication for thrombotic thrombocytopenic purpura. Added exclusion of concomitant TNFI therapy or other biologic DMARD Added exclusion of live vaccine within two weeks. Annual editorial review and reference update Annual editorial review Annual editorial review Annual editorial review and reference update Addition of Revlimid (lenalidomide) to combination therapy and defined NHL categories Annual review Annual review and reference update Revised RA statement: Inadequate treatment response, intolerance, or contraindication to one or more tumor necrosis factor (TNF) antagonist therapies This policy was approved by the FEP Pharmacy and Medical Policy Committee on December 3, 2015 and is effective on January 1, Deborah M. Smith, MD, MPH
Rituxan. Rituxan (rituximab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.10 Subject: Rituxan Page: 1 of 8 Last Review Date: June 22, 2017 Rituxan Description Rituxan (rituximab)
More informationRituxan. Rituxan (rituximab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.10 Subject: Rituxan Page: 1 of 9 Last Review Date: September 20, 2018 Rituxan Description Rituxan
More informationRituxan Hycela. Rituxan Hycela (rituximab and hyaluronidase human) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.96 Subject: Rituxan Hycela Page: 1 of 5 Last Review Date: September 15, 2017 Rituxan Hycela Description
More informationRituxan. Rituxan (rituximab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.10 Subject: Rituxan Page: 1 of 10 Last Review Date: September 19, 2013 Rituxan Description Rituxan
More informationGazyva. Gazyva (obinutuzumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.29 Subject: Gazyva Page: 1 of 7 Last Review Date: September 15, 2016 Gazyva Description Gazyva (obinutuzumab)
More informationGazyva. Gazyva (obinutuzumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.29 Subject: Gazyva Page: 1 of 7 Last Review Date: March 16, 2018 Gazyva Description Gazyva (obinutuzumab)
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Rituxan (rituximab) Policy Number: MP-031-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Issue Date: 11/01/2017
More informationSimponi / Simponi ARIA (golimumab)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 6 Last Review Date: September 15, 2016 Simponi / Simponi
More informationRITUXAN (rituximab and hyaluronidase human)
Drug Prior Authorization Guideline RITUXIMAB products J9310 RITUXAN (rituximab and hyaluronidase human) PA9847 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Cimzia Page: 1 of 5 Last Review Date: March 17, 2017 Cimzia Description Cimzia (certolizumab pegol)
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Subject: Cimzia Page: 1 of 5 Last Review Date: December 8, 2017 Cimzia Description Cimzia (certolizumab
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 5 Last Review Date: March 17, 2017 Xeljanz Description Xeljanz, Xeljanz
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi
More informationArzerra. Arzerra (ofatumumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.03 Subject: Arzerra Page: 1 of 5 Last Review Date: June 22, 2017 Arzerra Description Arzerra (ofatumumab)
More informationRegulatory Status FDA approved indication: Kineret is an interleukin-1 receptor antagonist indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.50 Subject: Kineret Page: 1 of 5 Last Review Date: March 17, 2017 Kineret Description Kineret (anakinra)
More informationRituxan (rituximab) DRUG POLICY BENEFIT APPLICATION
DRUG POLICY BENEFIT APPLICATION Rituxan (rituximab) Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations or exceptions
More informationRevlimid. Revlimid (lenalidomide) Description. Section: Prescription Drugs Effective Date: October 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.47 Subject: Revlimid Page: 1 of 7 Last Review Date: September 15, 2016 Revlimid Description Revlimid
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 5 Last Review Date: March 18, 2016 Xeljanz Description Xeljanz, Xeljanz
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 6 Last Review Date: December 8, 2017 Orencia Description Orencia (abatacept)
More informationRevlimid. Revlimid (lenalidomide) Description. Section: Prescription Drugs Effective Date: July 1, 2015
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.47 Subject: Revlimid Page: 1 of 6 Last Review Date: June 19, 2015 Revlimid Description Revlimid (lenalidomide)
More informationMEDICAL COVERAGE GUIDELINES ORIGINAL EFFECTIVE DATE: 08/19/14 SECTION: DRUGS LAST REVIEW DATE: LAST CRITERIA REVISION DATE: ARCHIVE DATE:
RITUXAN (rituximab) Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Medical Coverage Guideline
More informationClinical Policy: Rituximab (Rituxan) Reference Number: PA.CP.PHAR.260
Clinical Policy: (Rituxan) Reference Number: PA.CP.PHAR.260 Effective Date: 01/18 Last Review Date: 04/18 Coding Implications Revision Log Description The intent of the criteria is to ensure that patients
More informationGazyva (obinutuzumab)
STRENGTH DOSAGE FORM ROUTE GPID 1000mg/40mL Vial Intravenous 35532 MANUFACTURER Genentech, Inc. INDICATION(S) Gazyva (obinutuzumab) is a CD20- directed cytolytic antibody and is indicated, in combination
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): October 29, 2002 Most Recent Review Date (Revised): March 25, 2014 Effective Date: August 6, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT
More informationZydelig. Zydelig (idelalisib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.49 Subject: Zydelig Page: 1 of 6 Last Review Date: June 22, 2018 Zydelig Description Zydelig (idelalisib)
More informationZydelig. Zydelig (idelalisib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.49 Subject: Zydelig Page: 1 of 6 Last Review Date: June 22, 2017 Zydelig Description Zydelig (idelalisib)
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)
More informationNEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) Investor: Karl Mahler Thomas Kudsk Larsen (973)
NEWS RELEASE Genentech Contacts: Media: Joe St. Martin (650) 467-6800 Investor: Karl Mahler 011 41 61 687 8503 Thomas Kudsk Larsen (973) 235-3655 Biogen Idec Contacts: Media: Christina Chan (781) 464-3260
More informationImbruvica. Imbruvica (ibrutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.41 Subject: Imbruvica Page: 1 of 5 Last Review Date: June 22, 2017 Imbruvica Description Imbruvica
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.02 Subsection: Gastrointestinal nts Original Policy Date: May 20, 2011 Subject: Remicade Page: 1 of
More informationRegulatory Status FDA-approved indications: Entyvio is an α4β7integrin receptor antagonist indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.12 Subject: Entyvio Page: 1 of 7 Last Review Date: September 20, 2018 Entyvio Description Entyvio
More informationCorporate Medical Policy
Corporate Medical Policy Monoclonal Antibodies for Non-Hodgkin Lymphoma and Acute Myeloid File Name: Origination: Last CAP Review: Next CAP Review: Last Review: monoclonal_antibodies_for_non_hodgkin_lymphoma_acute_myeloid_leukemia
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More informationImbruvica. Imbruvica (ibrutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.41 Subject: Imbruvica Page: 1 of 5 Last Review Date: September 15, 2017 Imbruvica Description Imbruvica
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationCorporate Medical Policy
Corporate Medical Policy Rituximab for the Treatment of Rheumatoid Arthritis File Name: Origination: Last CAP Review: Next CAP Review: Last Review: rituximab_for_the_treatment_of_rheumatoid_arthritis 4/2008
More informationKymriah. Kymriah (tisagenlecleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.101 Subject: Kymriah Page: 1 of 5 Last Review Date: September 20, 2018 Kymriah Description Kymriah
More informationRemicade. Remicade (infliximab), Inflectra (infliximab-dyyb) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Remicade Page: 1 of 9 Last Review Date: June 22, 2017 Remicade Description Remicade (infliximab),
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Rituxan), and Hyaluronidase (Rituxan Hycela) Reference Number: CP.CPA.147 Effective Date: 11.11.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder
More informationAdministration Tear Pad
GPA & MPA Rituxan for GPA and MPA Administration Tear Pad RITUXAN, IN COMBINATION WITH GLUCOCORTICOIDS, IS THE ONLY FDA-APPROVED INDUCTION THERAPY FOR GRANULOMATOSIS WITH POLYANGIITIS (GPA) AND MICROSCOPIC
More informationIN A STUDY OF PATIENTS WITH GPA & MPA RITUXIMAB REGIMEN DEMONSTRATED CLINICALLY SIGNIFICANT REDUCTION OF MAJOR RELAPSE RATE VS AZA 1
FDA Approved for follow-up treatment 1 * IN A STUDY OF PATIENTS WITH GPA & MPA RITUXIMAB REGIMEN DEMONSTRATED CLINICALLY SIGNIFICANT REDUCTION OF MAJOR RELAPSE RATE VS AZA 1 Rituximab regimen=roche-manufactured,
More informationImmune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
More informationYescarta. Yescarta (axicabtagene ciloleucel) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.105 Subject: Yescarta Page: 1 of 5 Last Review Date: September 20, 2018 Yescarta Description Yescarta
More informationPolicy. Medical Policy Manual. Draft Revised Policy: Do Not Implement. Rituximab DESCRIPTION
Medical Manual Draft Revised : Do Not Implement Rituximab DESCRIPTION Rituximab is a genetically engineered monoclonal antibody which binds specifically to the human CD20 antigen. The CD20 antigen is expressed
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Rituximab (Rituxan), Rituximab and Hyaluronidase (Rituxan Hycela) Reference Number: CP.CPA.147 Effective Date: 11.11.16 Last Review Date: 05.18 Line of Business: Commercial Coding Implications
More informationOtezla. Otezla (apremilast) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background
More informationRituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous)
Rituxan Hycela (rituximab and hyaluronidase human) (Subcutaneous) Document Number: IC-0322 Last Review Date: 02/06/2018 Date of Origin: 7/20/2010 Dates Reviewed: 09/2010, 12/2010, 02/2011, 03/2011, 05/2011,
More informationGENENTECH AND BIOGEN IDEC RECEIVE A COMPLETE RESPONSE FROM FDA FOR EARLIER USE OF RITUXAN FOR RHEUMATOID ARTHRITIS
NEWS RELEASE Genentech Contacts: Media / Advocacy: Megan Pace (650) 467-7334 Investor: Susan Morris (650) 225-6523 Karl Mahler 011 41 61 68785 03 Biogen Idec Contacts: Media: Amy Reilly (617) 914-6524
More informationClinical Policy: Rituximab (Rituxan), Rituximab/Hyaluronidase (Rituxan Hycela) Reference Number: ERX.SPA.109 Effective Date:
Clinical Policy: Rituximab (Rituxan), Rituximab/Hyaluronidase (Rituxan Hycela) Reference Number: ERX.SPA.109 Effective Date: 10.01.16 Last Review Date: 11.18 Revision Log See Important Reminder at the
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 6 Last Review Date: December 8, 2017 Stelara Description Stelara (ustekinumab)
More informationChronic Lymphocytic Leukemia Update. Learning Objectives
Chronic Lymphocytic Leukemia Update Ashley Morris Engemann, PharmD, BCOP, CPP Clinical Associate Adult Stem Cell Transplant Program Duke University Medical Center August 8, 2015 Learning Objectives Recommend
More informationActemra. Actemra (tocilizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.12 Subject: Actemra Page: 1 of 13 Last Review Date: September 20, 2018 Actemra Description Actemra
More informationClinical Policy: Bendamustine (Bendeka, Treanda) Reference Number: CP.PHAR.307 Effective Date: Last Review Date: 11.18
Clinical Policy: (Bendeka, Treanda) Reference Number: CP.PHAR.307 Effective Date: 02.01.17 Last Review Date: 11.18 Coding Implications Revision Log Line of Business: Medicaid, HIM-Medical Benefit See Important
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Gazyva) Reference Number: CP.PHAR.305 Effective Date: 02.01.17 Last Review Date: 11.18 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important Reminder
More informationCalquence. Calquence (acalabrutinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.106 Subject: Calquence Page: 1 of 5 Last Review Date: March 16, 2018 Calquence Description Calquence
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
Program Number 2017 P 3041-8 Program Step Therapy Medications UnitedHealthcare Pharmacy Clinical Pharmacy Programs *Orencia (abatacept) *This step criteria refers to the subcutaneous formulation of abatacept
More informationActemra (tocilizumab) CG-DRUG-81
Market DC Actemra (tocilizumab) CG-DRUG-81 Override(s) Prior Authorization Approval Duration 1 year Medications Line of Business Quantity Limit Actemra (tocilizumab) vials VA MCD and All L-AGP May be subject
More informationRegulatory Status FDA-approved indication: Tysabri is an integrin receptor antagonist indicated for treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.08.27 1 of 6 Last Review Date: December 5, 2014 Tysabri Description Tysabri (natalizumab) Background
More informationBiologics for Autoimmune Diseases
Biologics for Autoimmune Diseases Goal(s): Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use. Promote use that is consistent with national clinical practice guidelines
More informationGazyva (obinutuzumab)
Gazyva (obinutuzumab) Line(s) of Business: HMO; PPO; QUEST Integration Medicare Advantage Original Effective Date: 10/01/2015 Current Effective Date: 01/01/201807/01/2018 POLICY A. INDICATIONS The indications
More informationClinical Policy: Idelalisib (Zydelig) Reference Number: ERX.SPA.269 Effective Date:
Clinical Policy: (Zydelig) Reference Number: ERX.SPA.269 Effective Date: 12.01.18 Last Review Date: 11.18 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Rituximab (Rituxan), Rituxan and Hyaluronidase (Rituxan Hycela) Reference Number: CP.PHAR.260 Effective Date: 07.16 Last Review Date: 05.18 Line of Business: Medicaid, HIM* Coding Implications
More informationRegulatory Status FDA-approved indication: Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Section: Prescription Drugs Effective Date: Oct 1, 2016 Subject: Enbrel Page: 1 of 7 Last Review Date:
More informationRegulatory Status FDA-approved indication: Humira and Amjevita are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.29 Subject: Humira Page: 1 of 10 Last Review Date: June 22, 2017 Humira Description Humira (adalimumab),
More informationACTEMRA (tocilizumab)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced
More informationInfliximab/Infliximab-dyyb DRUG.00002
Infliximab/Infliximab-dyyb DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Inflectra (inflectra-dyyb) Approval Duration 1 year Comment Intravenous administration
More informationGet the facts about WG, MPA, and Rituxan.
First approved treatment for adults with Wegener s granulomatosis (WG) and microscopic polyangiitis (MPA) Get the facts about WG, MPA, and Rituxan. {Brenda, living with Wegener s granulomatosis} INDICATION
More informationThe Medical Letter. on Drugs and Therapeutics
The Medical Letter publications are protected by US and international copyright laws. Forwarding, copying or any other distribution of this material is strictly prohibited. For further information call:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Rituximab (Rituxan), Rituxan/Hyaluronidase (Rituxan Hycela) Reference Number: CP.PHAR.260 Effective Date: 07.01.16 Last Review Date: 11.18 Line of Business: Medicaid, HIM* Coding Implications
More informationPolicy Number: PHARMACY T2 Effective Date: April 1, 2018
RITUXAN (RITUXIMAB) UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 004.24 T2 Effective Date: April 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE... 1 CONDITIONS OF COVERAGE... 1
More informationClinical Policy: Idelalisib (Zydelig) Reference Number: CP.CPA.278 Effective Date: Last Review Date: Line of Business: Commercial
Clinical Policy: (Zydelig) Reference Number: CP.CPA.278 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: golimumab_simponi 8/2013 2/2018 2/2019 3/2018 Description of Procedure or Service Golimumab (Simponi and
More informationClinical Policy: Obinutuzumab (Gazyva) Reference Number: CP.PHAR.305 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Gazyva) Reference Number: CP.PHAR.305 Effective Date: 02.01.17 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationRegulatory Status FDA-approved indication: Tysabri is an integrin receptor antagonist indicated for treatment of (1):
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.13 Subject: Tysabri Page: 1 of 6 Last Review Date: June 22, 2017 Tysabri Description Tysabri (natalizumab)
More information(tofacitinib) are met.
Xeljanz (tofacitinib) Policy Number: 5.01. 560 Origination: 3/2014 Last Review: 3/2014 Next Review: 3/2015 Policy BCBSKC will provide coverage for Xeljanz (tofacitinib) when it is determined to be medically
More informationInflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG CG-DRUG-64
Inflectra (infliximab-dyyb), Remicade (infliximab), Renflexis (infliximab-abda) DRUG.00002 CG-DRUG-64 Override(s) Prior Authorization *Washington Medicaid See State Specific Mandates Medications Inflectra
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More informationFinal Labeling Text
1.14.2.3 Final Labeling Text HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use Rituxan safely and effectively. See full prescribing information for
More informationRemicade (infliximab) DRUG.00002
Applicability/Effective Date *- Florida Healthy Kids Remicade (infliximab) DRUG.00002 Override(s) Prior Authorization Step Therapy Medications Remicade (infliximab) Approval Duration 1 year Comment Intravenous
More informationMedication Policy Manual. Topic: Arzerra, ofatumumab Date of Origin: January 15, 2010
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Policy No: dru196 Topic: Arzerra, ofatumumab Date of Origin: January 15, 2010 Committee Approval Date: January
More information1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes on the next page
COME HOME Non-Hodgkin pathway development worksheet, v6 September 2014 1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes
More informationNOTE: Should you have landed here as a result of a search engine (or other) link, be advised that these files contain material that is copyrighted by
NOTE: Should you have landed here as a result of a search engine (or other) link, be advised that these files contain material that is copyrighted by the American Medical Association. You are forbidden
More informationYESCARTA (axicabtagene ciloleucel)
YESCARTA (axicabtagene ciloleucel) Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices
More informationClinical Policy: Ibrutinib (Imbruvica) Reference Number: ERX.SPA.08 Effective Date:
Clinical Policy: (Imbruvica) Reference Number: ERX.SPA.08 Effective Date: 04.01.17 Last Review Date: 11.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
More informationCyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65
Market DC Cyltezo (adalimumab-adbm) CG-DRUG-64, CG-DRUG-65 Override(s) Prior Authorization Quantity Limit Medications Cyltezo (adalimumab-adbm) 40 mg/0.8 ml prefilled syringe #* ^ Approval Duration 1 year
More informationNotification to Implement Issued by pcodr: December 14, 2012
PROVINCIAL FUNDING SUMMARY Bendamustine hydrochloride (Treanda) for indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma (first-line and relapsed/refractory) perc Recommendation: Recommends For further
More informationNon-Hodgkin s Lymphomas Version
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Supportive Care for NHL Tumor Lysis Syndrome (TLS) Laboratory hallmarks of TLS:
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More information